This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74: 1405-18. doi: 10.1016/j. ijrobp.2008.10.091VianiGAStefanoEJAfonsoSLHigher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trialsInt J Radiat Oncol Biol Phys20097414051810.1016/j.ijrobp.2008.10.091Open DOISearch in Google Scholar
National Comprehensive Cancer Network I. NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. 2018 Version 4.2018. August 15, 2018: 34.National Comprehensive Cancer Network INCCN Clinical Practice Guidelines in Oncology. Prostate cancer2018Version 4.2018. August 15201834Search in Google Scholar
Deutsche Krebsgesellschaft DK, AWMF. Leitlinienprogramm Onkologie Interdisziplinäre leitlinie der qualität s3 zur früherkennung, diagnose und therapie der verschiedenen stadien des prostatakarzinoms 2018; Langversion 5.0:394.Deutsche Krebsgesellschaft DK, AWMFLeitlinienprogramm Onkologie Interdisziplinäre leitlinie der qualität s3 zur früherkennung, diagnose und therapie der verschiedenen stadien des prostatakarzinoms2018Langversion 5.0:394Search in Google Scholar
Wegener D, Zips D, Thorwarth D, Weiß J, Othman AE, Grosse U, et al. Precision of T2 TSE MRI-CT-image fusions based on gold fiducials and repetitive T2 TSE MRI-MRI-fusions for adaptive igrt of prostate cancer by using phantom and patient data. Acta Oncol 2019; 58: 88-94. doi: 10.1080/0284186X.2018.1518594WegenerDZipsDThorwarthDWeißJOthmanAEGrosseUet alPrecision of T2 TSE MRI-CT-image fusions based on gold fiducials and repetitive T2 TSE MRI-MRI-fusions for adaptive igrt of prostate cancer by using phantom and patient dataActa Oncol201958889410.1080/0284186X.2018.1518594Open DOISearch in Google Scholar
Monninkhof EM, van Loon JWL, van Vulpen M, Kerkmeijer LGW, Pos FJ, Haustermans K, et al. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the flame randomized controlled trial. Radiother Oncol 2018; 127: 74-80. doi: 10.1016/j.radonc.2017.12.022MonninkhofEMvan LoonJWLvan VulpenMKerkmeijerLGWPosFJHaustermansKet alStandard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the flame randomized controlled trialRadiother Oncol2018127748010.1016/j.radonc.2017.12.022Open DOISearch in Google Scholar
Schroeck FR, Jacobs BL, Bhayani SB, Nguyen PL, Penson D, Hu J. Cost of new technologies in prostate cancer treatment: systematic review of costs and cost effectiveness of robotic-assisted laparoscopic prostatectomy, intensity-modulated radiotherapy, and proton beam therapy. Eur Urol 2017; 72: 712-35. doi: 10.1016/j.eururo.2017.03.028SchroeckFRJacobsBLBhayaniSBNguyenPLPensonDHuJCost of new technologies in prostate cancer treatment: systematic review of costs and cost effectiveness of robotic-assisted laparoscopic prostatectomy, intensity-modulated radiotherapy, and proton beam therapyEur Urol2017727123510.1016/j.eururo.2017.03.028Open DOISearch in Google Scholar
Baum C, Alber M, Birkner M, Nüsslin F. Robust treatment planning for intensity modulated radiotherapy of prostate cancer based on coverage probabilities. Radiother Oncol 2006; 78: 27-35. doi: 10.1016/j.radonc.2005.09.005BaumCAlberMBirknerMNüsslinFRobust treatment planning for intensity modulated radiotherapy of prostate cancer based on coverage probabilitiesRadiother Oncol200678273510.1016/j.radonc.2005.09.005Open DOISearch in Google Scholar
Baum C, Birkner M, Alber M, Paulsen F, Nüsslin F. Dosimetric consequences of the application of off-line setup error correction protocols and a hull-volume definition strategy for intensity modulated radiotherapy of prostate cancer. Radiother Oncol 2005; 76: 35-42. doi: 10.1016/j.radonc.2005.06.006BaumCBirknerMAlberMPaulsenFNüsslinFDosimetric consequences of the application of off-line setup error correction protocols and a hull-volume definition strategy for intensity modulated radiotherapy of prostate cancerRadiother Oncol200576354210.1016/j.radonc.2005.06.006Open DOISearch in Google Scholar
Outaggarts Z, Wegener D, Berger B, Zips D, Paulsen F, Bleif M, et al. Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer. Acta Oncol 2020; 59: 911-7. doi: 10.1080/0284186X.2020.1760349.OutaggartsZWegenerDBergerBZipsDPaulsenFBleifMet alTarget miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancerActa Oncol202059911710.1080/0284186X.2020.1760349Open DOISearch in Google Scholar
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-81. doi: 10.1016/S1053-4296(03)00031-6TrottiAColevasADSetserARuschVJaquesDBudachVet alCTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSemin Radiat Oncol2003131768110.1016/S1053-4296(03)00031-6Open DOISearch in Google Scholar
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-6. doi: 10.1016/0360-3016(95)00060-CCoxJDStetzJPajakTFToxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)Int J Radiat Oncol Biol Phys1995311341610.1016/0360-3016(95)00060-COpen DOISearch in Google Scholar
National Cancer Institute USDOHAHS. Common terminology criteria for adverse events (CTCAE) Version 4.0. NIH Publication No 09-5410 2009: 1-196.National Cancer Institute USDOHAHS. Common terminology criteria for adverse events (CTCAE) Version 4.0NIH Publication No 09-541020091196Search in Google Scholar
Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Ph 2006; 65: 965-74. doi: 10.1016/j.ijrobp.2006.04.02RoachMHanksGThamesHSchellhammerPShipleyWUSokolGHet alDefining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceInt J Radiat Oncol Biol Ph2006659657410.1016/j.ijrobp.2006.04.02Open DOISearch in Google Scholar
Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 2014; 15: 464-73. doi: 10.1016/S1470-2045(14)70040-3DearnaleyDPJovicGSyndikusIKhooVCowanRAGrahamJDet alEscalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trialLancet Oncol2014154647310.1016/S1470-2045(14)70040-3Open DOISearch in Google Scholar
Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24: 1990-6. doi: 10.1200/JCO.2005.05.2530PeetersSTHeemsbergenWDKoperPCvan PuttenWLSlotADielwartMFet alDose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 GyJ Clin Oncol2006241990610.1200/JCO.2005.05.2530Open DOISearch in Google Scholar
Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 67-74. doi: 10.1200/JCO.2005.05.2530KubanDATuckerSLDongLStarkschallGHuangEHCheungMRet alLong-term results of the MD. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys200870677410.1200/JCO.2005.05.2530Open DOISearch in Google Scholar
Hall MD, Schultheiss TE, Smith DD, Tseng BP, Wong JY. The impact of increasing dose on overall survival in prostate cancer. Radiat Oncol 2015; 10: 115. doi: 10.1186/s13014-015-0419-3HallMDSchultheissTESmithDDTsengBPWongJYThe impact of increasing dose on overall survival in prostate cancerRadiat Oncol20151011510.1186/s13014-015-0419-3Open DOISearch in Google Scholar
Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010; 28: 1106-11. doi: 10.1200/JCO.2009.25.8475ZietmanALBaeKSlaterJDShipleyWUEfstathiouJACoenJJet alRandomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09J Clin Oncol20102811061110.1200/JCO.2009.25.8475Open DOISearch in Google Scholar
Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005; 294: 1233-9. doi: 10.1001/jama.294.10.1233ZietmanALDeSilvioMLSlaterJDRossiCJ JrMillerDWAdamsJAet alComparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trialJAMA20052941233910.1001/jama.294.10.1233Open DOISearch in Google Scholar
Goldner G, Dimopoulos J, Kirisits C, Pötter R. Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy. Strahlenther Onkol 2009; 185: 438-45. doi: 10.1007/s00066-2009-2033-5.GoldnerGDimopoulosJKirisitsCPötterRModerate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 GyStrahlenther Onkol20091854384510.1007/s00066-2009-2033-5Open DOISearch in Google Scholar
Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016; 375: 1425-37. doi: 10.1056/NEJMoa1606221DonovanJLHamdyFCLaneJAMasonMMetcalfeCWalshEet alPatient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancerN Engl J Med201637514253710.1056/NEJMoa1606221Open DOISearch in Google Scholar
Dorr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol 2001; 61: 223-31. doi: 10.1016/s0167-8140(01)00429-7DorrWHendryJHConsequential late effects in normal tissuesRadiother Oncol2001612233110.1016/s0167-8140(01)00429-7Open DOISearch in Google Scholar
Di Franco R, Borzillo V, Ravo V, Ametrano G, Cammarota F, Rossetti S, et al. Rectal/urinary toxicity after hypofractionated vs. conventional radiotherapy in high risk prostate cancer: systematic review and meta analysis. Eur Rev Med Pharmacol Sci 2017; 21: 3563-75. doi; 10.26355/eurrev_201708_13266DiFranco RBorzilloVRavoVAmetranoGCammarotaFRossettiSet alRectal/urinary toxicity after hypofractionated vsconventional radiotherapy in high risk prostate cancer: systematic review and meta analysis. Eur Rev Med Pharmacol Sci201721356375doi; 10.26355/eurrev_201708_13266Search in Google Scholar
Carvalho IT, Baccaglini W, Claros OR, Chen FK, Kayano PP, Lemos GC, et al. Genitourinary and gastrointestinal toxicity among patients with localized prostate cancer treated with conventional versus moderately hypofractionated radiation therapy: systematic review and meta-analysis. Acta Oncol 2018; 57: 1003-10. doi: 10.1080/0284186X.2018.1478126CarvalhoITBaccagliniWClarosORChenFKKayanoPPLemosGCet alGenitourinary and gastrointestinal toxicity among patients with localized prostate cancer treated with conventional versus moderately hypofractionated radiation therapy: systematic review and meta-analysisActa Oncol20185710031010.1080/0284186X.2018.147812629882448Open DOISearch in Google Scholar
Valdagni R, Kattan MW, Rancati T, Yu C, Vavassori V, Fellin G, et al. Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys 2012; 82: 1957-66. doi: 10.1016/j.ijrobp.2011.03.028ValdagniRKattanMWRancatiTYuCVavassoriVFellinGet alIs it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndromeInt J Radiat Oncol Biol Phys20128219576610.1016/j.ijrobp.2011.03.028Open DOISearch in Google Scholar
Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (hypro): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 2016; 17: 464-74. doi: 10.1016/S1470-2045(15)00567-7AluwiniSPosFSchimmelEKrolSvan derToorn PPet alHypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (hypro): late toxicity results from a randomised, non-inferiority, phase 3 trialLancet Oncol2016174647410.1016/S1470-2045(15)00567-7Open DOISearch in Google Scholar
Jolnerovski M, Salleron J, Beckendorf V, Peiffert D, Baumann AS, Bernier V, et al. Intensity-modulated radiation therapy from 70 Gy to 80 Gy in prostate cancer: six- year outcomes and predictors of late toxicity. Radiat Oncol 2017; 12: 99. doi: 10.1186/s13014-017-0839-3JolnerovskiMSalleronJBeckendorfVPeiffertDBaumannASBernierVet alIntensity-modulated radiation therapy from 70 Gy to 80 Gy in prostate cancer: six- year outcomes and predictors of late toxicityRadiat Oncol2017129910.1186/s13014-017-0839-3547310428622770Open DOISearch in Google Scholar
Eckert F, Alloussi S, Paulsen F, Bamberg M, Zips D, Spillner P, et al. Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer. BMC Cancer 2013; 13: 27. doi: 10.1186/1471-2407-13-27.EckertFAlloussiSPaulsenFBambergMZipsDSpillnerPet alProspective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancerBMC Cancer2013132710.1186/1471-2407-13-27355840223336502Open DOISearch in Google Scholar
Ramlov A, Assenholt MS, Jensen MF, Grønborg C, Nout R, Alber M, et al. Clinical implementation of coverage probability planning for nodal boosting in locally advanced cervical cancer. Radiother Oncol 2017; 123: 158-63. doi: 10.1016/j.radonc.2017.01.015RamlovAAssenholtMSJensenMFGrønborgCNoutRAlberMet alClinical implementation of coverage probability planning for nodal boosting in locally advanced cervical cancerRadiother Oncol20171231586310.1016/j.radonc.2017.01.01528190601Open DOISearch in Google Scholar
